Ministry of food and drug safety

Ministry of food and drug safety

home > Our Works > Bio&Cosmetics > Manufactures
Manufactures|Bio&Cosmetics|Our Works|Minisry of Food and Drug Safety

Biological Products

(Cell therapy products) ANTEROGEN
  • Registration Date 2017-02-15
  • Hit 5006

Company Information

1. Name

ANTEROGEN

2. Website Address

http://www.anterogen.com

3. Location

(Namsung Plaza, Gasan-dong) 405, 130 Digital-ro, Geumcheon-gu,

Seoul (08589), South Korea

4. Contacts

+82 2 2104 0391

Pharmaceutical Product Information

1. Brand Name

Cupistem®

2. Active Ingredient

Autologous adipose tissue-derived mesenchymal stem cell

3. Indication

Crohn’s Fistula

4. Information

Cupistem® was approved as adipose tissue-derived mesenchymal stem cell (ASC) product first time in the world by Korean Ministry of Food and Drug Safety (MFDS) as of Jan 2012 and its medical insurance price was granted as of Jan 2014 by Health Insurance Review & Assessment Service (HIRA). The most remarkable feature of this product comes from its sustainability of therapeutic efficacy.

Cupistem® showed that 82% of patients with complex Crohn’s fistula achieved complete healing at week 8 after treatment, 81% out of them sustained response at week 96.

Anterogen explained this astonishing sustainability of product efficacy from immune modulation effect by ASC manufactured by Anterogen.

5. Images

Pharmaceutical Product Information

1. Brand Name

Queencell®

2. Active Ingredient

Autologous adipose tissue-derived adipose cell by minimal manipulation

3. Indication

Subcutaneous tissue defect

4. Information

Queencell® was approved as “autologous adipose tissue-derived adipose cell produced by minimal manipulation” by Korean Ministry of Food and Drug Safety (MFDS) as of Mar 2010.

Queencell® is comprised of stromal vascular fraction (SVF) that is a heterogeneous mixture of mesenchymal stem cells and other cell types such as preadipocytes, endothelial progenitor cells, pericytes, mast cells, and fibroblast.

Queencell® is effective in treating subcutaneous tissue defect.

5. Images


Attached File

Division

Written by 한지혜